stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Net income
NeoGenomics, Inc.'s net income for fiscal 2025 was −$108.0M, compared with −$78.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$32.3M. Over the past ten years it has ranged from −$144.3M (fiscal 2022) to $8.0M (fiscal 2019); the current reading is higher than 18% of that period. NeoGenomics, Inc. ranks 37th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$108.0M | — |
| FY2024 | −$78.7M | — |
| FY2023 | −$88.0M | — |
| FY2022 | −$144.3M | — |
| FY2021 | −$8.3M | — |
| FY2020 | $4.2M | (47.89%) |
| FY2019 | $8.0M | 203.26% |
| FY2018 | $2.6M | — |
| FY2017 | −$396.0K | — |
| FY2016 | −$6.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$7.5M | — |
| Jun 2026 | $2.2M | — |
| Mar 2026 | −$17.1M | — |
| Dec 2025 | −$9.9M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| CDNA CareDx, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $126.8M |
| FRNM Freenome, Inc compare | −$762.6K |
| CSTL Castle Biosciences, Inc. compare | −$23.0M |
| NEO NeoGenomics, Inc. | −$32.3M |
| ADPT Adaptive Biotechnologies Corporation compare | −$70.7M |
| WGS GeneDx Holdings Corp. compare | −$106.4M |
| PSNL Personalis, Inc. compare | −$119.3M |
| OPK OPKO Health, Inc. compare | −$148.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on NEO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement